- Home
- IOVA vs NUWE Comparison
IOVA vs NUWE Comparison
Compare IOVA & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NUWE
- Stock Information
- Founded
- IOVA 2007
- NUWE 1999
- Country
- IOVA United States
- NUWE United States
- Employees
- IOVA N/A
- NUWE N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IOVA Health Care
- NUWE Health Care
- Exchange
- IOVA Nasdaq
- NUWE Nasdaq
- Market Cap
- IOVA 1.0B
- NUWE 3.9M
- IPO Year
- IOVA N/A
- NUWE N/A
- Fundamental
- Price
- IOVA $3.62
- NUWE $0.95
- Analyst Decision
- IOVA Strong Buy
- NUWE Strong Buy
- Analyst Count
- IOVA 9
- NUWE 1
- Target Price
- IOVA $18.22
- NUWE $17.00
- AVG Volume (30 Days)
- IOVA 10.2M
- NUWE 66.9K
- Earning Date
- IOVA 05-08-2025
- NUWE 05-06-2025
- Dividend Yield
- IOVA N/A
- NUWE N/A
- EPS Growth
- IOVA N/A
- NUWE N/A
- EPS
- IOVA N/A
- NUWE N/A
- Revenue
- IOVA $164,070,000.00
- NUWE $8,740,000.00
- Revenue This Year
- IOVA $182.20
- NUWE $22.96
- Revenue Next Year
- IOVA $62.10
- NUWE $29.97
- P/E Ratio
- IOVA N/A
- NUWE N/A
- Revenue Growth
- IOVA 13698.99
- NUWE N/A
- 52 Week Low
- IOVA $2.70
- NUWE $0.75
- 52 Week High
- IOVA $14.23
- NUWE $12.60
- Technical
- Relative Strength Index (RSI)
- IOVA 51.94
- NUWE 53.14
- Support Level
- IOVA $2.89
- NUWE $0.86
- Resistance Level
- IOVA $3.43
- NUWE $0.95
- Average True Range (ATR)
- IOVA 0.32
- NUWE 0.08
- MACD
- IOVA 0.09
- NUWE 0.02
- Stochastic Oscillator
- IOVA 86.17
- NUWE 92.59
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.